Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1.
Antisense oligonucleotides (ASOs) have demonstrated variation of efficacy in patient populations. This has prompted our investigation into the contribution of genetic architecture to ASO pharmacokinetics (PK) and pharmacodynamics (PD). Genome wide association (GWA) and transcriptomic analysis in a h...
Main Authors: | Elaine Pirie, Shayoni Ray, Calvin Pan, Wuxia Fu, Andrew F Powers, Danielle Polikoff, Colton M Miller, Katrina M Kudrna, Edward N Harris, Aldons J Lusis, Rosanne M Crooke, Richard G Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2018-10-01
|
Series: | PLoS Genetics |
Online Access: | http://europepmc.org/articles/PMC6224167?pdf=render |
Similar Items
-
Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice[S]
by: Adam E. Mullick, et al.
Published: (2011-05-01) -
Antisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- mice
by: Thomas A. Bell, III, et al.
Published: (2013-10-01) -
Comparison of the pharmacological profiles of murine antisense oligonucleotides targeting apolipoprotein B and microsomal triglyceride transfer protein
by: Richard G. Lee, et al.
Published: (2013-03-01) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
by: Ashok Verma
Published: (2018-01-01) -
Defining the factors that contribute to on-target specificity of antisense oligonucleotides.
by: Walt F Lima, et al.
Published: (2014-01-01)